|Other Names||Vesicle transport through interaction with t-SNAREs homolog 1A, Vesicle transport v-SNARE protein Vti1-like 2, Vti1-rp2, VTI1A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8602b was selected from the C-term region of human VTI1A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||V-SNARE that mediates vesicle transport pathways through interactions with t-SNAREs on the target membrane. These interactions are proposed to mediate aspects of the specificity of vesicle trafficking and to promote fusion of the lipid bilayers. Involved in vesicular transport from the late endosomes to the trans-Golgi network. Along with VAMP7, involved in an non- conventional RAB1-dependent traffic route to the cell surface used by KCNIP1 and KCND2. May be involved in increased cytokine secretion associated with cellular senescence.|
|Cellular Location||Cytoplasmic vesicle. Golgi apparatus membrane; Single-pass type IV membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
V-SNARE that mediates vesicle transport pathways through interactions with t-SNAREs on the target membrane. These interactions are proposed to mediate aspects of the specificity of vesicle trafficking and to promote fusion of the lipid bilayers. It may be concerned with increased secretion of cytokines associated with cellular senescence.
Tai,G., et.al., Mol. Biol. Cell 15 (9), 4011-4022 (2004)Mallard,F., et.al., J. Cell Biol. 156 (4), 653-664 (2002)
If you have any additional inquiries please email technical services at email@example.com.